2016 was a breakthrough year for Modified Citrus Pectin (MCP) research, with six new independent studies published on its broad-spectrum benefits in areas such as heart disease, kidney and liver failure, metastatic cancer, inflammation, and aging. Made from citrus peels, MCP stands out from other natural health supplements due to its singular ability to bind the rogue protein and aging biomarker, Galectin-3 (Gal-3).
Gal-3 Protein: A Hidden Age Accelerator
Gal-3 has been identified as a key player in accelerated cellular degeneration and aging. When Gal-3 levels are too high, this protein adversely affects cellular communication, allowing cancer cells to aggregate and spread, and fueling chronic inflammation and fibrosis of organs and tissues, that ultimately suppress immunity and accelerate the aging process. Gal-3 blood tests are available as a measure of cardiovascular health, as well as integrative practitioners using it to track progression in areas such as cancer and aging.
Taking Control of Gal-3 With Modified Citrus Pectin
Tackling the degenerative effects of elevated Gal-3 lies in Modified Citrus Pectin. In fact, MCP is becoming recognized as the only available Gal-3 blocker, capable of addressing the damage it causes and protecting essential aspects of health. Important to note, MCP must be the correct molecular weight and structure to be effective, between 3-15 kilodaltons (as shown in published literature). This small size allows the MCP to absorb into the circulation and perform its critical benefits throughout the body.
2016 MCP Research Highlights
The six new independent studies published in 2016 highlighted the power of MCP’s broad-spectrum benefits. These studies include:
- In a Plos One study, MCP was shown to block Gal-3 in an animal model of spinal injury, reducing pain and temperature sensitivity, as well as other indicators of inflammation.
- A Hypertension study found that MCP blocked Gal-3 in the left ventricle of the heart and suppressed genes related to fibrogenesis, ultimately preventing cardiac fibrosis and damage.
- In the Canadian Journal of Physiology and Pharmacology, a study showed MCP reducing fibrosis and inflammation in a model of liver damage by blocking Gal-3, inducing apoptosis and supporting antioxidant activities.
- The International Journal of Obesity study demonstrated MCP blocking Gal-3 to prevent inflammation and fat tissue remodeling in a model of obesity, resulting in important implications in metabolic diseases.
- A study in the Journal of the American Heart Association showed MCP blocking Gal-3 to prevent valve calcification in a model of atherosclerosis and decreased inflammation and fibrosis in aortic valves.
- In a PLos One study, MCP was shown to block Gal-3 in two kidney tissue damage models, reducing fibrosis and supporting healthy kidney function.
The Importance of MCP for Health and Aging
Over the past 25 years, numerous clinical and preclinical studies have demonstrated Modified Citrus Pectin’s benefits in cellular, detoxification, and immune health. As research continues, MCP is gaining international recognition as the solution to halt and reverse the effects of elevated Gal-3.
For additional information on MCP, the book “New Twist on Health: Modified Citrus Pectin for Cancer, Heart Disease and More” by Karolyn Gazella is an excellent resource. As research progresses, more integrative physicians and health-conscious consumers are incorporating MCP as a central part of their daily health protocols.
